Experimental pain pill cuts opioid use after surgery in Phase IIb trial

A patient recovering from a tummy tuck took an experimental pill while reporting pain of at least 5 out of 10. Within an hour, LTG-001 began reducing that pain, and over the next 48 hours both tested doses outperformed placebo in a Phase IIb trial of 343 adults.

The drug targets Nav1.8, a voltage-gated sodium channel — a gate that helps electrical signals move through nerves — found mainly in the peripheral nervous system. It is concentrated in pain-sensing nerve cells and helps carry pain signals. Blocking it aims to interrupt pain closer to its source, rather than activating opioid receptors in the brain and body.

The high-dose regimen produced an average pain reduction score of 185.30, compared with 161.05 for the low-dose regimen. More than half of the patients receiving the high dose — 52% — completed recovery without a backup opioid, compared with 22% of patients given placebo. Both LTG-001 doses reached meaningful pain relief faster than the opioid group and the placebo group.

That result matters because opioids remain effective but can bring addiction and overdose risks, along with nausea, constipation and vomiting. Earlier Nav1.8 inhibitors had produced only modest pain relief, and one follow-up drug failed to beat placebo. LTG-001 is designed to penetrate deep into peripheral nerves and reach the point where pain signals begin.

So what changes in practice? Not yet a new standard of care, but potentially another tool for patients leaving surgery. The figures come from a controlled trial, and the high-dose result was not a direct head-to-head comparison with hydrocodone-acetaminophen. Larger studies must still establish whether LTG-001 is safe and consistently effective before doctors can rely on it instead of opioids.